84. Sarcoidosis Clinical trials / Disease details
Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04758650 (ClinicalTrials.gov) | January 26, 2021 | 12/2/2021 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and Cardiac sarcoïdosis. | Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and Cardiac sarcoïdosis | Squamous Cell Carcinoma of Head and Neck;Cancer;Carotid Stenosis;Atherosclerosis of Artery;Hodgkin Lymphoma, Adult;Non Hodgkin Lymphoma;HLH;Cardiac Sarcoidosis | Drug: 68GaNOTA-Anti-MMR-VHH2 | Universitair Ziekenhuis Brussel | NULL | Recruiting | 18 Years | N/A | All | 140 | Phase 2 | Belgium |